As Goldman writes big check in eye care, others steer clear of retail health
It’s Thursday, and more than one private equity fund has taken a victory lap this week in healthcare. Wowza.
To start, the largest-ever sponsor transaction in the vision-care space kicked off the week, with Goldman’s PE arm striking a $2.7 billion deal for Altas and CDPQ’s MyEyDr. Read my story for more info.
Other firms making bold moves were Genstar, preempting the process for Advarra through an about $1.3 billion deal for the Linden– and Northlane-backed provider of compliance-type services for clinical research. Linden is poised to generate a handsome return, I am told.
Finally, Advent — just weeks after its bet in home care — put a quick stop to the process for Spectrum Equity’s Definitive Healthcare. The firm invested in the healthcare data provider in a deal valued around $1.7 billion, sources told me.
In notable exits, Bain Capital and Diamond Capital this morning disclosed an agreement to sell Beacon Health Options to Anthem. What are the metrics on the deal? Shoot me a note at firstname.lastname@example.org.
In the midst of the flurry of activity … I also got the chance to swing by the Jefferies Healthcare Conference at the Grand Hyatt in NYC, where a June 4 panel of PE executives discussed market dynamics.
Why some large-cap sponsors are avoiding retail health
While we may have seen one of 2019’s biggest bets in retail health this week, some large-cap sponsors are opting out of the segment, which is often considered the most recession resilient.
SUBSCRIBE to get the Healthcare Wire in your inbox every Thursday morning. It’s free!